Insider Transactions in Q1 2024 at Jazz Pharmaceuticals PLC (JAZZ)
Insider Transaction List (Q1 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 07
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,768
-21.14%
|
$205,088
$116.98 P/Share
|
Mar 06
2024
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,936
-9.86%
|
$230,384
$119.18 P/Share
|
Mar 05
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,622
-5.97%
|
$423,774
$117.53 P/Share
|
Mar 05
2024
|
Bruce C Cozadd Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
22,436
-4.96%
|
$2,625,012
$117.53 P/Share
|
Mar 05
2024
|
Robert Iannone EVP, Global Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,294
-6.46%
|
$502,398
$117.53 P/Share
|
Mar 05
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,432
-7.62%
|
$401,544
$117.53 P/Share
|
Mar 05
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,474
-12.76%
|
$289,458
$117.53 P/Share
|
Mar 01
2024
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,987
+22.48%
|
-
|
Mar 01
2024
|
Mary Elizabeth Henderson SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,178
+24.52%
|
-
|
Mar 01
2024
|
Neena M Patil EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,348
+21.51%
|
-
|
Mar 01
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,065
+20.71%
|
-
|
Mar 01
2024
|
Robert Iannone EVP, Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
16,928
+20.29%
|
-
|
Mar 01
2024
|
Renee D Gala President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
19,916
+24.7%
|
-
|
Mar 01
2024
|
Patrick Kennedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,423
+50.0%
|
-
|
Mar 01
2024
|
Bruce C Cozadd Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,187
+9.99%
|
-
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+30.05%
|
$1,428,000
$119.65 P/Share
|
Mar 01
2024
|
Philip L Johnson EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,932
+50.0%
|
-
|
Jan 17
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,038
-6.75%
|
$123,522
$119.13 P/Share
|
Jan 17
2024
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,210
+12.57%
|
-
|
Jan 17
2024
|
Robert Iannone EVP, Global Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-3.37%
|
$205,870
$119.13 P/Share
|
Jan 17
2024
|
Robert Iannone EVP, Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,970
+10.42%
|
-
|
Jan 17
2024
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,656
-4.82%
|
$197,064
$119.13 P/Share
|
Jan 17
2024
|
Neena M Patil EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,087
+12.89%
|
-
|
Jan 17
2024
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,327
+15.27%
|
-
|
Jan 17
2024
|
Bruce C Cozadd Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,245
-2.96%
|
$1,457,155
$119.13 P/Share
|
Jan 17
2024
|
Bruce C Cozadd Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,545
+6.02%
|
-
|
Jan 17
2024
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,204
-7.28%
|
$381,276
$119.13 P/Share
|
Jan 17
2024
|
Renee D Gala President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
7,079
+13.86%
|
-
|